29 Apr 2021

UCB's General Meeting of Shareholders 2021

Read More
28 Apr 2021

UCB Announces PDUFA Date for Bimekizumab

Read More
23 Apr 2021

Acquisitions of own shares and disposals of own shares

Read More
23 Apr 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Read More
23 Apr 2021

The New England Journal of Medicine Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Read More
22 Apr 2021

UCB’s zilucoplan shows no relevant effect in immune-mediated necrotizing myopathy (IMNM)

Read More
20 Apr 2021

Acquisitions of own shares and Disposals of own shares

Read More
16 Apr 2021

UCB showcases new research at the 73rd American Academy of Neurology Annual Meeting to demonstrate broad neurology leadership and future portfolio

Read More
14 Apr 2021

Notice of Early Redemption - €350 million € 1.875% fixed rate notes due 2 April 2022

Read More
9 Apr 2021

Acquisitions of own shares and Disposals of own shares

Read More
Subscribe to